Paper · 32315352

INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.

Liu PCC and 26 others. PLoS One, 2020. Cited by 144 papers, by iCite.

11 sourcespapers-2026-11-12-0.1.0

Cite this record

ConductScience Library. INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models. Papers, record 32315352. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32315352

On this page

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title: INCB054828 (pemigatinib), a potent and selective inhibitor of fibroblast growth factor receptors 1, 2, and 3, displays activity against genetically defined tumor models.; PubMed
Journal: PLoS One; PubMed
Year: 2020; PubMed
Publication types: Journal Article, Research Support, Non-U.S. Gov't; PubMed
PubMed: https://pubmed.ncbi.nlm.nih.gov/32315352/; PubMed
DOI: https://doi.org/10.1371/journal.pone.0231877; PubMed
PMC: https://pmc.ncbi.nlm.nih.gov/articles/PMC7313537/; PubMed
The journal: https://conductscience.org/library/journal-index/101285081; PubMed
Citations, by iCite: 144; iCite
Relative citation ratio, by iCite: 6.18; iCite
Revised in PubMed: 2020-07-24; PubMed

Authors27

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

Order	Author	Forename
1	Liu PCC	Phillip C C
2	Koblish H	Holly
3	Wu L	Liangxing
4	Bowman K	Kevin
5	Diamond S	Sharon
6	DiMatteo D	Darlise
7	Zhang Y	Yue
8	Hansbury M	Michael
9	Rupar M	Mark
10	Wen X	Xiaoming

1 to 10 of 27Source PubMed

See all 27 authors

Topics21

NLM's MeSH indexing of the paper, its major topics first.

MeSH term	Major
Morpholines	Major topic
Neoplasms	Major topic
Protein Kinase Inhibitors	Major topic
Pyrimidines	Major topic
Pyrroles	Major topic
Receptor, Fibroblast Growth Factor, Type 1	Major topic
Receptor, Fibroblast Growth Factor, Type 2	Major topic
Receptor, Fibroblast Growth Factor, Type 3	Major topic
Administration, Oral
Animals
Cell Line, Tumor
Female
Half-Life
Humans
Mice
Mice, Inbred C57BL
Mice, Nude
Mice, SCID
Rats
Rats, Nude
Xenograft Model Antitumor Assays

Source PubMed

Grants0

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

None in this release.

Trials0

The trials whose ClinicalTrials.gov record lists the paper, and the trial numbers the paper's PubMed record names.

None in this release.

Comments and corrections0

PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.

None in this release.

References42

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

Order	PMID	Title	Journal	Year	In Papers	Source
1	29,848,605	Efficacy of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Inhibitor, in Patients with Previously Treated Advanced Urothelial Carcinoma with FGFR3 Alterations.	Cancer Discov	2018	https://conductscience.org/library/papers/29848605	PubMed
2	21,119,661	Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo.	Br J Cancer	2011	https://conductscience.org/library/papers/21119661	PubMed
3	24,550,739	Integrated genomic characterization reveals novel, therapeutically relevant drug targets in FGFR and EGFR pathways in sporadic intrahepatic cholangiocarcinoma.	PLoS Genet	2014	https://conductscience.org/library/papers/24550739	PubMed
4	24,393,342	Targeted inhibition of the FGF19-FGFR4 pathway in hepatocellular carcinoma; translational safety considerations.	Liver Int	2014	https://conductscience.org/library/papers/24393342	PubMed
5	23,175,443	Oncogenic FGFR3 gene fusions in bladder cancer.	Hum Mol Genet	2013	https://conductscience.org/library/papers/23175443	PubMed
6	10,647,931	The hallmarks of cancer.	Cell	2000	https://conductscience.org/library/papers/10647931	PubMed
7	20,226,962	8p11 myeloproliferative syndrome: a review.	Hum Pathol	2010	https://conductscience.org/library/papers/20226962	PubMed
8	17,912,529	Role of FGFR3 in urothelial cell carcinoma: biomarker and potential therapeutic target.	World J Urol	2007	https://conductscience.org/library/papers/17912529	PubMed
9	10,809,780	Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4.	J Biol Chem	2000	https://conductscience.org/library/papers/10809780	PubMed
10	22,837,387	Transforming fusions of FGFR and TACC genes in human glioblastoma.	Science	2012	https://conductscience.org/library/papers/22837387	PubMed

1 to 10 of 42

See all 42 references

Cited by85

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 144 citations.

PMID	Title	Journal	Year	In Papers	Source
42,679,332	Sequencing of Fibroblast Growth Factor Receptor Inhibitors in Cholangiocarcinoma: A Review of Published Cases.	JCO Precis Oncol	2026	https://conductscience.org/library/papers/42679332	PubMed
42,177,363	FGFR3 oncogenic activation drives oxidative metabolic reprogramming in bladder cancer: a systems metabolomics approach.	Commun Biol	2026	https://conductscience.org/library/papers/42177363	PubMed
42,058,998	FGFR alterations and potential role of FGFR inhibitors in pediatric brain tumors.	Neurooncol Adv	2026	https://conductscience.org/library/papers/42058998	PubMed
41,420,106	Mechanisms of resistance to VHL loss-induced genetic and pharmacological vulnerabilities.	EMBO Mol Med	2026	https://conductscience.org/library/papers/41420106	PubMed
41,226,200	Protein-Ligand Interactions in Cardiometabolic Drug Targets: Focus on Weight Loss and Cardioprotection.	Molecules	2025	https://conductscience.org/library/papers/41226200	PubMed
41,090,357	Pharmacologic inhibition of IRE1α-dependent decay protects alveolar epithelial identity and prevents pulmonary fibrosis in mice.	J Clin Invest	2025	https://conductscience.org/library/papers/41090357	PubMed
41,084,837	Dabogratinib (TYRA-300), an FGFR3 Isoform-Selective Inhibitor: Preclinical and Initial Clinical Evidence of Antitumor Activity.	Mol Cancer Ther	2026	https://conductscience.org/library/papers/41084837	PubMed
41,002,392	FGFR1 Inhibition by Pemigatinib Enhances Radiosensitivity in Glioblastoma Stem Cells Through S100A4 Downregulation.	Cells	2025	https://conductscience.org/library/papers/41002392	PubMed
40,781,553	Exploiting collateral sensitivity in the evolution of resistance to tyrosine kinase inhibitors in soft tissue sarcomas.	Commun Biol	2025	https://conductscience.org/library/papers/40781553	PubMed
40,762,256	Protein kinase B inhibitors enhance the sensitivity of translocated promoter region-fibroblast growth factor receptor 1 cells to fibroblast growth factor receptor 1 inhibitor-induced apoptosis.	J Int Med Res	2025	https://conductscience.org/library/papers/40762256	PubMed

1 to 10 of 85

See all 85 cited by

Genes25

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

Gene	NCBI Gene ID	Linked by	In Genes	Source
ABL1	25	PubTator's text mining	https://conductscience.org/library/genes/25	NCBI Gene
AKT1	207	PubTator's text mining	https://conductscience.org/library/genes/207	NCBI Gene
ALK	238	PubTator's text mining	https://conductscience.org/library/genes/238	NCBI Gene
CCP110	9,738	PubTator's text mining	https://conductscience.org/library/genes/9738	NCBI Gene
CD34	947	PubTator's text mining	https://conductscience.org/library/genes/947	NCBI Gene
CYP3A4	1,576	PubTator's text mining	https://conductscience.org/library/genes/1576	NCBI Gene
EGFR	1,956	PubTator's text mining	https://conductscience.org/library/genes/1956	NCBI Gene
ETV6	2,120	PubTator's text mining	https://conductscience.org/library/genes/2120	NCBI Gene
FGF23	8,074	PubTator's text mining	https://conductscience.org/library/genes/8074	NCBI Gene
FGFR1	2,260	PubTator's text mining	https://conductscience.org/library/genes/2260	NCBI Gene

1 to 10 of 25

See all 25 genes

Drugs0

The drugs whose trials, in the Pipelines release, list the paper.

None in this release.

Data0

The data bank entries PubMed's record names. Trial numbers are under Trials.

None in this release.

Data dates

The date of each source this release read.

PubMed: 2026-11-06; PubMed
iCite: 2026-11-05; iCite
PMC's ID file: 2026-11-05; PMC's ID file
NIH RePORTER's grant and paper links: 2026-11-01; NIH RePORTER's grant and paper links
Trials: 2026-11-12
Gene search: 2026-11-11
Pipelines: 2026-09-18

Sources 11

ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
HGNCCC0
iCiteCC BY 4.0
NCBI GenePublic domain (US government)
NIH RePORTER's grant and paper linksPublic domain
Open TargetsCC0 1.0
PMC's ID filePublic domain (US government)
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0

Each source's terms

ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
HGNCCC0: https://www.genenames.org/about/license/
iCiteCC BY 4.0
NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
PubMedNLM's terms
PubTator 3Public domain
UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/32315352

GET https://conductscience.org/api/papers/v1/32315352/authors?page=2

API reference For AI assistants